SCHEMBL4485635

SCHEMBL4485635

Cc1cc2ccccc2nc1N1CCC(C)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.66
ALDH1A1 P00352 7/20 0.58
KMT2A Q03164 6/20 0.53
MEN1 O00255 5/20 0.53
PKM P14618 1/20 0.53
LMNA P02545 5/20 0.51
TRPC3 Q13507 1/20 0.51
HTT P42858 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
PDE10A Q9Y233 1/20 0.48
KDM4E B2RXH2 6/20 0.48
MAPT P10636 5/20 0.48
HPGD P15428 3/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
NPSR1 Q6W5P4 2/20 0.47
TP53 P04637 2/20 0.47
ATM Q13315 2/20 0.47
USP2 O75604 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14259051 0.83 KDM4E (0.62) TSHRALDH1A1KMT2AMEN1LMNA
SCHEMBL6770354 0.81 ADRB1 (0.56) TSHRALDH1A1LMNAHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL5141053 0.81 KDM4E (0.61) TSHRALDH1A1KMT2AMEN1LMNA
Hydrochloric Acid SCHEMBL30222843 0.80 ADRB1 (0.55) TSHRALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL29947184 0.80 KDM4E (0.67) TSHRALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL31515779 0.78 CNR2 (0.47) TSHRALDH1A1KMT2AMEN1LMNA
SCHEMBL5910406 0.78 HRH3 (0.58) TSHRALDH1A1KMT2ALMNAHTT
SCHEMBL26734873 0.73 KDM4E (0.49) TSHRALDH1A1KMT2AMEN1LMNA
SCHEMBL11978706 0.73 HTR3A (0.68) TSHRKMT2ALMNATRPC3HTT
SCHEMBL9910134 0.72 HTR3A (0.69) TSHRKMT2AMEN1PKMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205083-B1 Substituted aryl sulfone derivatives as calcium channel blockers MERCK SHARP & DOHME (US) 2013-07-17 EP disclosed
US-7524862-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-28 US disclosed
EP-1737839-A1 NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-03 EP disclosed
US-20050267115-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-12-01 US disclosed
WO-2005103029-A1 NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267115-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 TSHR 96/4885ALDH1A1 3033/4885KMT2A 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.